364 PATENT ABSTRACTS

parasite or other whole microorganism. The complex of antigen coupled to antibody may be used in immunizing a higher animal against an antigen.

5173294

D N A P R O B E F O R T H E I D E N T I F I C A T I O N O F

H A E M O P H I L U S I N F L U E N Z A E

Timothy F Murphy, Michael A Apicella as- signed to Research Foundation of State Univer- sity of New York

A plasmid which contains a genetic code for an immunogenic portion which is conserved in many strains of nontypable Haemophilus in- fluenzae and the bacterium containing this plas- mid is disclosed. The immunogenic portion is preferably an epitope on an outer membrane protein of H. influenzae. A monoclonal anti- body to the immunogenic portion and the hybridoma which will produce the monoclonal antibody is also included. The invention further includes a DNA probe constructed to cor- respond to the nucleic acids which code for the immunogenic portion. This probe may be label- led with a radioactive marker and may be used as a diagnostic tool to assay various clinical sam- ples for the presence of H. influenzae.

5173399

M O U S E M O N O C L O N A L A N T I B O D I E S T O H I V - I P 2 4 A N D

T H E I R U S E I N D I A G N O S T I C T E S T S

Smriti U Mehta, Jeffrey C Hunt, Sushil G Devare assigned to Abbott Laboratories

The present invention provides monoclonal antibodies demonstrating specific reactivity with HIV-1 p24. One monoclonal antibody designated 31-42-19 recognizes an unique epit- ope on HIV-I p24 that is not immunogenic in humans. 31-42-19 also reacts with an anti- genicaUy cross reactive epitope on HIV-2 p24. Another monoclonal antibody designated 31- 90-25 recognizes an epitope within a highly immunogenic region of HIV-I p24. The present invention also provides cell lines capable of pro- ducing these monoclonal antibodies. The inven- tion also includes a highly sensitive enzyme immunoassay for the detection of HIV-I p24 in

biological fluids, using a monoclonal antibody mixture. The present invention further provides methods for the use of these monoclonal anti- bodies for the detection of anti-HIV-1 p24 anti- bodies and HIV-2 p24 antigen in biological samples.

5173415

P R O C E S S F O R R E M O V A L O F V I R U S E S F R O M S O L U T I O N S O F

P H Y S I O L O G I C A L L Y A C T I V E S U B S T A N C E S

Hajim Hiratani, Jun Tateishi, Tetsuyuki Kitamoto, Sennan, Japan assigned to Japan Chemical Research Co Ltd

A membrane filter of 0.025 to 0.05 mu in pore size is treated by passing the solution of a water- soluble high molecular substance such as albumin, dextran, polyvinylpyrrolidone, poly- sorbate 80, gelatin or the like through the mem- brane filter. Employing the filter thus treated, the solution of a physiologically active substance of human origin such as human growth hor- mone, kallikrein, trypsin inhibitor, epidermal growth factor, leucocyte interferon etc. is filtered at high recovery rate of the active substance avoiding the adsorption of the active substance onto the filter. By the filtration, harmful viruses such as Creutzfeldt-Jacob disease pathogen which may exist in the physiologically active sub- stance can be removed.

5173420

M O N O C L O N A L A N T I B O D Y R E C O G N I Z I N G U N - N A T U R A L

G A N G L I O S I D E G D 3

Reiji Kannagi, Yoshiko Kirihata, Tomoya Ogawa, Masaaki Numata, Mamoru Sugimoto, Kyoto, Japan assigned to MECT Corporation

A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc alpha2 right arrow9NeuAc terminal. A monoelonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc alpha2 right arrowfGal beta terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc al- pha2 right arrow9NeuAc terminal, NeuAc al- pha2 right arrow6Gal beta terminal and NeuAc